Souheil Abdel Nour
Critical Care Medicine · Matthews, NCNPI 1255511028
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 73.9% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $1,367 and has fallen 70.2% since, to $408 in 2025.
Across 44 payments — averaging $46.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- AstraZeneca$100
- GSK$95
- Actelion Pharmaceuticals US, Inc.$89
- Insmed, Inc.$86
- Sunovion Pharmaceuticals Inc.$52
- plus $114 from 5 others
What the payments were for
- Travel & lodging$93646%
- Food & beverage$1,08953%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 19 | $1,519 |
| AstraZeneca | 4 | $100 |
| GSK | 5 | $95 |
| Actelion Pharmaceuticals US, Inc. | 1 | $89 |
| Insmed, Inc. | 3 | $86 |
| Sunovion Pharmaceuticals Inc. | 6 | $52 |
| United Therapeutics Corporation | 1 | $28 |
| Merck | 2 | $27 |
| Viatris Specialty LLC | 1 | $22 |
| Philips North America LLC | 1 | $20 |
| Electromed, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUMISITE$1,165
How this compares
$2,054 in reported general payments places this provider in the 80th percentile of 190 critical care medicine providers in North Carolina.
See all critical care medicine providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 23 | $283,572 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 332 | $259,452 |
| LetairisAmbrisentan | 12 | $155,812 |
| Breo ElliptaFluticasone/Vilanterol | 208 | $97,937 |
| Incruse ElliptaUmeclidinium Bromide | 96 | $43,281 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 80 | $38,269 |
| SymbicortBudesonide/Formoterol Fumarate | 109 | $37,966 |
| Spiriva RespimatTiotropium Bromide | 55 | $33,151 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $27,591 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 43 | $25,523 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 25 | $12,203 |
| Arnuity ElliptaFluticasone Furoate | 44 | $12,125 |
| Spiriva HandihalerTiotropium Bromide | 16 | $11,137 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 368 | $10,836 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $9,698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $95 | $451,064760 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $100 | $65,556149 claims |
| MerckDulera | $27 | $8,37520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 190 critical care medicine providers in North Carolina.
Other critical care medicine in Matthews
- Navneet AroraMatthews$23K
- Maciej WalczyszynMatthews$2K
- Alexis SmithHuntersville$726K
- Rabih BecharaCharlotte$453K
- Ashish KhannaWinston Salem$364K
- Alan HeffnerCharlotte$326K
- Daniel FeinsteinPinehurst$213K
- Daniel FoxRaleigh$133K
- Hassan YousafWinston Salem$97K
- Neil MacintyreDurham$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.